Trial ID or NCT#

NCT00450385

Status

not recruiting iconNOT RECRUITING

Purpose

The investigators hypothesize that survival of newly diagnosed DLBCL (diffuse large B-cell lymphoma) patients treated with R-CHOP can be predicted by RNA or protein gene expression or by presence of biomarkers associated with the anti-tumor effects of Rituximab.

Official Title

Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP

Eligibility Criteria

Ages Eligible for Study: 18 Years to 120 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ronald Levy, MD
Ronald Levy, MD
Medical oncologist, Lymphoma specialist
Robert K. and Helen K. Summy Professor in the School of Medicine
Ranjana Advani
Ranjana Advani
Medical oncologist, Lymphoma specialist
Saul A. Rosenberg, MD, Professor of Lymphoma
Ash A. Alizadeh, MD/PhD
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor

Contact us to find out if this trial is right for you.

CONTACT

Cancer Clinical Trials Office
(650) 498-7061